Core Viewpoint - The meeting between Zhang Chaochao, the Secretary of the Municipal Party Committee, and Wang Jian, the co-founder and chairman of BGI Group, aims to deepen strategic cooperation and promote complementary advantages in the life sciences sector, ultimately benefiting the public [1][2]. Group 1: Strategic Cooperation - The meeting highlighted the importance of collaboration between BGI Group and Shijiazhuang, focusing on sustainable development and market economy principles in areas such as basic research, result transformation, biomedicine, and health [2][3]. - A framework agreement for the co-construction of the "China Population Health and Major Diseases Multimodal Holographic Database" was signed between the High-tech Zone and BGI Group [4]. Group 2: Economic and Social Development - Zhang Chaochao emphasized the positive trends in Shijiazhuang's economic and social development, including industrial growth, urban construction, and improvements in living standards and ecological governance [2]. - Wang Jian expressed gratitude for the support from Shijiazhuang and noted the city's impressive industrial development and business-friendly environment, indicating BGI Group's strong interest in future collaborations [3].

证券代码：300676 证券简称：华大基因 公告编号：2025-039 注：本次质押股份不涉及负担重大资产重组等业绩补偿义务。 （二）控股股东及其一致行动人股份累计质押情况 一、控股股东及其一致行动人部分股份质押的基本情况 | | 是否为控股 股东或第一 | 本次质押数 | 占其所持 | | 是否为限 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 占公司 | 售股（如 | 是否为 | 质押起 | 质押到期 | | 质押用 | | 股东名称 | 大股东及其 | 量（股） | 股份比例 | 总股本 | 是，注明 | 补充质 | 始日 | 日 | 质权人 | 途 | | | 一致行动人 | | | 比例 | 限售类 | 押 | | | | | | | | | | | 型） | | | | 中国邮政 | | | | | | | | | | | 至办理解 | 储蓄银行 | 自身生 | | 深圳华大 | | | | | | | | | | | | 基因科技 | 是 | | | | 否 | ...

证券代码：300676 证券简称：华大基因 公告编号：2025-038 深圳华大基因股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司控股股东 深圳华大基因科技有限公司（以下简称华大控股）的通知，获悉华大控股将其持有的 部分公司股份办理了质押，相应的质押登记手续已通过中国证券登记结算有限责任 公司深圳分公司办理完毕。现将具体事项公告如下： 一、控股股东及其一致行动人部分股份质押的基本情况 | | 是否为控股 股东或第一 | 本次质押数 | | | 是否为限 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 占其所持 | 占公司 | 售股（如 | 是否为 | 质押起 | 质押到期 | | 质押用 | | 股东名称 | 大股东及其 | 量（股） | 股份比例 | 总股本 | 是，注明 | 补充质 | 始日 | 日 | 质权人 | 途 | ...

6月10日， 华大基因 发布华大肿瘤用药与遗传分析知识库——遗传性肿瘤变异知识库和肿瘤体细胞变异 与用药知识库，填补了国内肿瘤精准诊疗数据产品空白，打造国内基于真实世界基因 大数据 的医疗知 识库范例。 此外，华大基因与深圳数据交易所正式达成战略合作，致力于数据产品创新孵化、行业数据标准建设、 数据合规安全、数据资产金融化以及数据空间建设等关键领域。 华大基因CEO赵立见在发布会前接受了记者的采访，分享了华大基因近年来如何超前布局，积极应 对"卡脖子"问题，探索变数据资源为数据资产，主动迎接 人工智能 为生命科学带来的机遇与挑战。 激活医疗 数据要素 乘数效应 提升中国基因检测产业 全球影响力 展望未来，赵立见告诉记者，华大基因将以肿瘤防控为起点，向生育健康、传染病防控、慢性病管理、 133111i主动健康管理新范式四大核心领域延伸，目标是通过数据整合，实现"防诊治康"全链路覆盖。 据赵立见介绍，"遗传性肿瘤变异知识库"覆盖了170多个基因、19万个变异，专注于遗传性肿瘤的早筛 与遗传咨询；"肿瘤体细胞变异与用药知识库"则整合了3000多个基因、2000余种药物及5万多个变异， 为精准用药决策提供科学依据。 ...

证券代码：300676 证券简称：华大基因 公告编号：2025-037 近日，公司已完成注册地址的工商变更登记手续以及《公司章程》的工商备 案手续，公司注册地址由"深圳市盐田区洪安三街21号华大综合园7栋7层-14层" 变更为"深圳市盐田区梅沙街道滨海社区云华路9号华大时空中心B栋8南1-1"， 并取得了深圳市市场监督管理局换发的《营业执照》。同时，根据工商登记机关 最终核准的注册地址对《公司章程》进行相应条款的修订。 除上述注册地址变更的修订条款外，《公司章程》其他条款内容不变。 三、备查文件 1、《深圳华大基因股份有限公司营业执照》； 2、深圳市市场监督管理局出具的变更登记和换发证照通知书。 深圳华大基因股份有限公司 关于完成注册地址变更并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、公司注册地址变更的情况说明 深圳华大基因股份有限公司（以下简称"公司"）分别于2025年4月24日、2025 年5月20日召开第四届董事会第五次会议、2024年年度股东会，审议通过《关于变 更注册地址并修订<公司章程>的议案》。具体内容详见公司于20 ...

Group 1 - The 11th China (Shanghai) International Technology Import and Export Fair has attracted nearly a thousand exhibitors from around 20 countries and regions, showcasing innovative achievements and building an international technology cooperation network [1] - The United Nations Industrial Development Organization emphasizes support for technology innovation and transfer, focusing on green transformation, digital technology, artificial intelligence, and South-South cooperation as priority areas [1] - Glasgow, as the overseas guest city, aims to strengthen cooperation with China in clean energy, particularly in offshore wind power, highlighting the fair's focus on green low-carbon and medical technology sectors [1] Group 2 - The Peru exhibition team is interested in collaborating in agriculture, manufacturing, irrigation, and mining technology, benefiting economically and socially from deep cooperation with China [2] - Shenzhen serves as the domestic guest city, with BGI showcasing its "GenSIRO-16" AI-based high-throughput gene testing solution, having established partnerships with over 3,000 overseas medical and research institutions [2] - Shanghai's technology import and export contract amount has seen an average annual growth of 8.6% since the 14th Five-Year Plan, with a projected amount of $21.33 billion in 2024, marking a 17.7% year-on-year increase and setting a historical record [2]

Core Viewpoint - BGI Genomics has officially established a strategic partnership with the Shenzhen Data Exchange, launching its first comprehensive tumor database, marking a significant step towards transforming into a data-driven intelligent medical ecosystem [2][9]. Group 1: Strategic Cooperation - The partnership aims to deepen collaboration in key areas such as data product innovation, industry data standard construction, data compliance and security, financialization of data assets, and data space development [2]. - BGI Genomics is transitioning from a traditional genetic testing service provider to a data-driven intelligent medical ecosystem, leveraging its proprietary platform and technological advantages to build a comprehensive database reflecting the genetic characteristics of the Chinese population [9][11]. - The cooperation is seen as a critical move to construct an autonomous data ecosystem and implement the national strategy of "data elements × healthcare" [9]. Group 2: Industry Context - The global precision medicine market is experiencing rapid growth, and China's data element market reform is making significant breakthroughs, with Shenzhen leading the way by establishing a data exchange and regulatory framework for compliant data circulation [4][5]. - The collaboration is positioned as a key starting point for the value development of genetic data, aiming to explore innovative paths for compliant development and application of genetic data [11]. - The initiative addresses critical industry challenges such as data security, privacy protection, and complex regulatory compliance, providing a systematic framework to enhance overall governance in the sector [13]. Group 3: Product Launch - BGI Genomics has launched a gene data product, the comprehensive tumor database, which integrates authoritative global genetic variation and treatment data while focusing on clinical guidelines and practice data unique to China [13]. - This product aims to provide high-value data services for precision medicine research and alleviate challenges associated with reliance on international databases [13].

Group 1 - Medical device sector shows strong performance with ETF fund (159797) experiencing significant trading volume and net inflow of funds [1] - Recent policy document issued on June 9 aims to improve healthcare resources and insurance mechanisms, which is seen as a major driver for pharmaceutical companies [3] - Citic Securities predicts a trend of low-to-high earnings growth in the medical device sector, with significant improvements expected in the second half of the year [4] Group 2 - Structural investment opportunities exist within the medical device sector, with certain companies expected to achieve high growth in Q2 and Q3 [5] - The easing of US-China tariffs is beneficial for medical device companies, potentially lowering production costs and expanding overseas market share [6] - The medical device ETF fund (159797) covers core areas such as medical equipment and in vitro diagnostics, with top ten weighted stocks accounting for 46.78% [6][7]

重要内容提示： 1、本次归属股票上市流通日：2025 年 6 月 11 日（星期三）； 2、本次归属人数：421 人（首次授予与预留授予归属人数存在部分重合）， 其中，首次授予部分第二个归属期归属人数为 417 人；预留授予部分第一个归属 期归属人数为 18 人； 深圳华大基因股份有限公司 关于 2022 年限制性股票激励计划首次授予部分第二个归属期及 预留授予部分第一个归属期归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：300676 证券简称：华大基因 公告编号：2025-036 一、本激励计划实施情况概要 （一）本激励计划简述及授予情况 1 3、本次归属股票数量：249.55 万股，占公司目前总股本的 0.60%；其中，首 次授予部分第二个归属期归属股票数量 179.55 万股，预留授予部分第一个归属期 归属股票数量 70 万股； 4、本次归属的限制性股票授予价格（调整后）：27.73 元/股； 公司于 2022 年 11 月 18 日、2022 年 12 月 6 日分别召开第三届董事会第十三 次会议、2022 年第五 ...

Group 1 - The assisted reproductive concept sector increased by 3.33%, ranking 10th among concept sectors, with 68 stocks rising, including Haichen Pharmaceutical which hit a 20% limit up, and others like Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical also reaching their limit up [1][2] - Notable gainers in the assisted reproductive sector included Xinghao Pharmaceutical, Shengnuo Biological, and Saiseng Pharmaceutical, which rose by 27.29%, 17.58%, and 6.08% respectively [1][6] - The sector saw a net inflow of 414 million yuan from main funds, with 31 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow, led by Zhongsheng Pharmaceutical with a net inflow of 247 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio in the assisted reproductive sector were Zhongsheng Pharmaceutical at 55.08%, Shuanglu Pharmaceutical at 20.11%, and Meinuo Pharmaceutical at 17.33% [3][4] - The trading volume and turnover rates for leading stocks in the sector were significant, with Zhongsheng Pharmaceutical showing a daily increase of 9.99% and a turnover rate of 3.84% [3][4] - Other stocks with notable performance included Fuxing Pharmaceutical with a 3.60% increase and a turnover rate of 2.17%, and Meinuo Pharmaceutical with a 9.97% increase and a turnover rate of 7.37% [3][4]